Compounds > 3,4-dihydroxyphenylacetic acid

3,4-dihydroxyphenylacetic acid and nebicapone

3,4-dihydroxyphenylacetic acid has been researched along with nebicapone in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hainzl, D; Loureiro, AI; Parada, A; Soares-da-Silva, P; Vieira-Coelho, MA	1

Other Studies

1 other study(ies) available for 3,4-dihydroxyphenylacetic acid and nebicapone

Article	Year
BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation. European journal of pharmacology, 2001, May-18, Volume: 420, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Biological Availability; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Methylation; Rats; Rats, Wistar; Time Factors; Tyrosine	2001

Article

Year

BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.

European journal of pharmacology, 2001, May-18, Volume: 420, Issue:1

Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Biological Availability; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Methylation; Rats; Rats, Wistar; Time Factors; Tyrosine

2001